Combination of HDAC and topoisomerase inhibitors in small cell lung cancer

por Gray, Jhanelle, Cubitt, Christopher L., Zhang, Shumin, Chiappori, Alberto
Publicado em 2012

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents

por Turner, Joel G., Dawson, Jana, Cubitt, Christopher L., Baz, Rachid, Sullivan, Daniel M.
Publicado em 2014

Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines

por Welch, Darcy, Kahen, Elliot, Fridley, Brooke, Brohl, Andrew S., Cubitt, Christopher L., Reed, Damon R.
Publicado no PLoS One (2019)

MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines

por Almhanna, Khaldoun, Cubitt, Christopher L, Zhang, Shumin, Kazim, Sabiha, Husain, Kazim, Sullivan, Dan, Sebti, Said, Malafa, Mokenge
Publicado em 2013

Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma

por Kahen, Elliot, Yu, Diana, Harrison, Douglas J., Clark, Justine, Hingorani, Pooja, Cubitt, Christopher L., Reed, Damon R.
Publicado no Cancer Chemother Pharmacol (2016)

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo

por Turner, Joel G., Dawson, Jana, Emmons, Michael F., Cubitt, Christopher L., Kauffman, Michael, Shacham, Sharon, Hazlehurst, Lori A., Sullivan, Daniel M.
Publicado em 2013

Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma

por Yu, Diana, Kahen, Elliot, Cubitt, Christopher L., McGuire, Jeremy, Kreahling, Jenny, Lee, Jae, Altiok, Soner, Lynch, Conor C., Sullivan, Daniel M., Reed, Damon R.
Publicado no Sci Rep (2015)

Inhibition of ER stress–associated IRE-1/XBP-1 pathway reduces leukemic cell survival

por Tang, Chih-Hang Anthony, Ranatunga, Sujeewa, Kriss, Crystina L., Cubitt, Christopher L., Tao, Jianguo, Pinilla-Ibarz, Javier A., Del Valle, Juan R., Hu, Chih-Chi Andrew
Publicado em 2014

Melphalan and exportin 1 inhibitors exert synergistic anti-tumor effects in preclinical models of human multiple myeloma

por Turner, Joel G., Cui, Yan, Bauer, Alexis A., Dawson, Jana L., Gomez, Juan A., Kim, Jongphil, Cubitt, Christopher L., Nishihori, Taiga, Dalton, William S., Sullivan, Daniel M.
Publicado no Cancer Res (2020)

Rapid Screening of Novel Agents for Combination Therapy in Sarcomas

por Cubitt, Christopher L., Menth, Jiliana, Dawson, Jana, Martinez, Gary V., Foroutan, Parastou, Morse, David L., Bui, Marilyn M., Letson, G. Douglas, Sullivan, Daniel M., Reed, Damon R.
Publicado em 2013

Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors conta...

por Garrett, Christopher R., Coppola, Domenico, Wenham, Robert M., Cubitt, Christopher L., Neuger, Anthony M., Frost, Timothy J., Lush, Richard M., Sullivan, Daniel M., Cheng, Jin Q., Sebti, Saïd M.
Publicado no Invest New Drugs (2010)

Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining T(reg) and antitumor CTL function

por Betts, Brian C., Veerapathran, Anandharaman, Pidala, Joseph, Yang, Hua, Horna, Pedro, Walton, Kelly, Cubitt, Christopher L., Gunawan, Steven, Lawrence, Harshani R., Lawrence, Nicholas J., Sebti, Said M., Anasetti, Claudio
Publicado no Sci Transl Med (2017)

Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors

por Kahen, Elliot John, Brohl, Andrew, Yu, Diana, Welch, Darcy, Cubitt, Christopher L., Lee, Jae K., Chen, Yunyun, Yoder, Sean J., Teer, Jamie K., Zhang, Yonghong O., Wallace, Margaret R., Reed, Damon R.
Publicado no Oncotarget (2018)

Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia

por Sweet, Kendra, Komrokji, Rami, Padron, Eric, Cubitt, Christopher L., Turner, Joel G., Zhou, Junmin, List, Alan F., Sallman, David A., Dawson, Jana L., Sullivan, Daniel M., Chavez, Julio, Shah, Bijal D., Lancet, Jeffrey E.
Publicado no Clin Cancer Res (2019)

Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases

por Schonbrunn, Ernst, Betzi, Stephane, Alam, Riazul, Martin, Mathew P., Becker, Andreas, Han, Huijong, Francis, Rawle, Chakrasali, Ramappa, Jakkaraj, Sudhakar, Kazi, Aslamuzzaman, Sebti, Said M., Cubitt, Christopher L., Gebhard, Anthony W., Hazlehurst, Lori A., Tash, Joseph S., Georg, Gunda I.
Publicado em 2013

A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth

por MARCHION, DOUGLAS C., BICAKU, ELONA, XIONG, YIN, ZGHEIB, NADIM BOU, SAWAH, ENTIDHAR AL, STICKLES, XIAOMANG BA, JUDSON, PATRICIA L., LOPEZ, ALEX S., CUBITT, CHRISTOPHER L., GONZALEZ-BOSQUET, JESUS, WENHAM, ROBERT M., APTE, SACHIN M., BERGLUND, ANDERS, LANCASTER, JOHNATHAN M.
Publicado no Oncol Rep (2013)

The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer

por ZGHEIB, NADIM BOU, XIONG, YIN, MARCHION, DOUGLAS C., BICAKU, ELONA, CHON, HYE SOOK, STICKLES, XIAOMANG BA, AL SAWAH, ENTIDHAR, JUDSON, PATRICIA L., HAKAM, ARDESHIR, GONZALEZ-BOSQUET, JESUS, WENHAM, ROBERT M., APTE, SACHIN M., CUBITT, CHRISTOPHER L., CHEN, DUNG TSA, LANCASTER, JOHNATHAN M.
Publicado em 2012

Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival

por BUSH, STEPHEN H., TOLLIN, SHARON, MARCHION, DOUGLAS C., XIONG, YIN, ABBASI, FOROUGH, RAMIREZ, INGRID J., ZGHEIB, NADIM BOU, BOAC, BERNADETTE, JUDSON, PATRICIA L., CHON, HYE SOOK, WENHAM, ROBERT M., APTE, SACHIN M., CUBITT, CHRISTOPHER L., BERGLUND, ANDERS E., HAVRILESKY, LAURA J., LANCASTER, JOHNATHAN M.
Publicado no Mol Clin Oncol (2016)